BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 8302681)

  • 1. Prescription drugs and health care reform.
    Gibaldi M
    Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
    Margolis RE
    Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
    [No Abstract]   [Full Text] [Related]  

  • 3. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 4. RX for nosebleed prices.
    Greenwald J
    Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
    [No Abstract]   [Full Text] [Related]  

  • 5. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
    Sherrid P
    US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
    [No Abstract]   [Full Text] [Related]  

  • 7. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 8. Vertical integration: the drug industry and prescription benefits managers.
    Gibaldi M
    Pharmacotherapy; 1995; 15(3):265-71. PubMed ID: 7667161
    [No Abstract]   [Full Text] [Related]  

  • 9. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 10. To cut costs, risky drug use.
    Consum Rep; 2011 Nov; 76(11):9. PubMed ID: 22022754
    [No Abstract]   [Full Text] [Related]  

  • 11. Health care reform: pharmaceutical industry sees itself as 'whipping boy'.
    Gatty B
    Hosp Formul; 1993 Oct; 28(10):872, 871. PubMed ID: 10129137
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AWP reimbursement scrutinized by several states.
    Carroll J
    Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 15. [Generic medicines].
    Peláez de Loño J
    Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription medications: effect on healthcare costs and dentistry.
    Capehart KL
    Dent Today; 2005 Apr; 24(4):12, 14. PubMed ID: 15884605
    [No Abstract]   [Full Text] [Related]  

  • 18. The rising utilization and costs of prescription drugs.
    PHC4 FYI; 2004; (26):1-2. PubMed ID: 15344277
    [No Abstract]   [Full Text] [Related]  

  • 19. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic-class wars--drug promotion in a competitive marketplace.
    Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP
    N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.